Add BrightSurf on Google Email

Addition of antioxidants to cell cultures can enhance the production of monoclonal antibodies, promising therapeutics for a range of health conditions

The addition of antioxidants to cell cultures can improve the production of monoclonal antibodies by reducing oxidative stress and increasing cell viability. This has potential benefits for therapies targeting cancer and autoimmune diseases.

SourceSociety of Chemical Industry·JournalJournal of Chemical Technology and Biotechnology·TypeExperimental study·DateFeb 15, 2023

A new tool in the arsenal against COVID-19 is being put to the test

A new class of SARS-CoV-2 antibodies has been shown to neutralise multiple variants of the virus, providing hope for a better antiviral medication. The antibodies work by attaching to a partially hidden part of the virus' spike protein that would be difficult for it to mutate.

SourceGarvan Institute of Medical Research·JournalNature Communications·TypeExperimental study·DateFeb 14, 2023
Meta Quest 3 512GB

Meta Quest 3 512GB enables immersive mission planning, terrain rehearsal, and interactive STEM demos with high-resolution mixed-reality experiences.

CU researchers show that Paxlovid remains highly effective on Omicron variants

Researchers from the University of Colorado found that Paxlovid significantly reduced rates of hospitalization and death among non-hospitalized patients infected with recent Omicron subvariants. The study used real-world data from 28,000 patients and suggested a benefit for Paxlovid in preventing severe disease.

SourceUniversity of Colorado Anschutz Medical Campus·JournalThe Lancet·DateFeb 10, 2023

Small study shows promise for antimalarial monoclonal antibody to prevent malaria

Researchers at the University of Maryland School of Medicine found that monoclonal antibody CIS43LS provided high levels of protection against controlled human malaria infection. The study's findings suggest that this treatment could be a potential game changer for deploying monoclonal antibody therapies in African countries.

SourceUniversity of Maryland School of Medicine·JournalThe Lancet Infectious Diseases·TypeRandomized controlled/clinical trial·DateJan 25, 2023

New biomarker strategy devised to screen for, diagnose deadly heart complication from cancer treatment

Researchers at Michigan Medicine have developed a new biomarker-based strategy to screen for immune checkpoint inhibitor-induced myocarditis, which can cause muscle damage and liver injury. Early detection of these biomarkers can lead to earlier treatment and improved survival rates.

SourceMichigan Medicine - University of Michigan·JournalJACC CardioOncology·TypeObservational study·DateDec 20, 2022
Apple iPhone 17 Pro

Apple iPhone 17 Pro delivers top performance and advanced cameras for field documentation, data collection, and secure research communications.

How antibody therapy impacts COVID vaccines

Research finds that individuals who received monoclonal antibodies before COVID vaccination exhibit a diverse antibody response, increasing the coverage provided by vaccines. This phenomenon, known as antibody feedback inhibition, is beneficial for diversifying immune responses to viruses.

SourceRockefeller University·JournalNature·DateDec 6, 2022

Discovery of antibody structure could lead to treatment for Crimean Congo Hemorrhagic Fever virus

A research team at the University of California, Riverside has discovered the structure of a human monoclonal antibody that protects against Crimean Congo Hemorrhagic Fever virus. The study provides insights into fighting a broad range of viral strains and could lead to targeted therapeutics for infected patients.

SourceUniversity of California - Riverside·JournalNature Communications·TypeExperimental study·DateNov 28, 2022

Albert Einstein College of Medicine researchers develop promising new cancer therapy

Scientists at Albert Einstein College of Medicine describe findings that could bolster the effectiveness of immune-checkpoint therapy by using natural killer (NK) cells. The research team developed a monoclonal antibody targeting KIR2DL5, which allowed NK cells to vigorously attack and shrink human tumors.

SourceAlbert Einstein College of Medicine·JournalJournal of Clinical Investigation·TypeExperimental study·DateNov 15, 2022
Fluke 87V Industrial Digital Multimeter

Fluke 87V Industrial Digital Multimeter is a trusted meter for precise measurements during instrument integration, repairs, and field diagnostics.

Ankle replacement and fusion demonstrate similar effectiveness for end-stage ankle osteoarthritis

A randomized controlled trial found that both total ankle replacement and ankle fusion improve quality of life and have similar clinical scores in patients with end-stage ankle osteoarthritis. However, TAR is associated with greater wound-healing complications and nerve injuries, while AF is linked to more blood clots and nonunion of t...

SourceAmerican College of Physicians·JournalAnnals of Internal Medicine·TypeRandomized controlled/clinical trial·DateNov 14, 2022

Anifrolumab shows long-term promise in patients with lupus

Researchers report positive results from the first placebo-controlled trial of anifrolumab, a human monoclonal antibody targeting type I interferon receptor in patients with lupus. Treatment with anifrolumab was well-tolerated and sustained reduction in lupus disease activity.

SourceWiley·JournalArthritis & Rheumatology·DateNov 12, 2022

Monoclonal antibodies preserve stem cells in mouse brains, bring promise for future studies

Researchers used monoclonal antibodies to suppress the immune system in mice, tracking human neural stem cell survival using luciferase. The study reveals that monoclonal antibody-mediated immunosuppression enabled long-term survival of transplanted human neural stem cells in mouse brains for at least six to eight months.

SourceMichigan Medicine - University of Michigan·JournalClinical and Translational Medicine·TypeExperimental study·DateNov 9, 2022

Scientists define independent subtype of idiopathic multicentric Castleman disease

Idiopathic plasmacytic lymphadenopathy (IPL) has been confirmed as a distinct clinicopathologically uniform disease, which can be reclassified into an independent subtype of idiopathic multicentric Castleman disease (iMCD). IPL showed greater plasmacytosis and hyperplastic germinal centers compared to non-IPL groups.

SourceOkayama University·JournalInternational Journal of Molecular Sciences·TypeExperimental study·DateNov 4, 2022
GQ GMC-500Plus Geiger Counter

GQ GMC-500Plus Geiger Counter logs beta, gamma, and X-ray levels for environmental monitoring, training labs, and safety demonstrations.

Monoclonal antibody prevents malaria infection in African adults

A monoclonal antibody was found to be up to 88.2% effective at preventing malaria infection in healthy, non-pregnant adults during a six-month malaria season in Mali, Africa. The study suggests that this antibody could complement other measures to protect vulnerable groups from seasonal malaria.

SourceNIH/National Institute of Allergy and Infectious Diseases·JournalNew England Journal of Medicine·DateOct 31, 2022

Experimental monoclonal antibodies show promise against Epstein-Barr virus

Researchers developed investigational monoclonal antibodies targeting EBV's gH and gL proteins, blocking infection in human cells and providing nearly complete protection against EBV infection in mice. The findings highlight viable vaccine targets and potential treatment options for immunocompromised patients.

SourceNIH/National Institute of Allergy and Infectious Diseases·JournalImmunity·DateOct 27, 2022

New Omicron subvariant largely evades neutralizing antibodies

A study reveals that BA.2.75.2, a new Omicron sublineage, largely evades neutralizing antibodies and is resistant to several monoclonal antibody treatments, posing an increased risk of SARS-CoV-2 infections this winter.

SourceKarolinska Institutet·JournalThe Lancet Infectious Diseases·TypeExperimental study·DateOct 14, 2022

Monoclonal antibody improves cat allergen immunotherapy

A new approach to allergy treatment has shown promise in reducing symptoms of allergic rhinitis by 36% after just one year of treatment. The combination of a monoclonal antibody with cat allergy shots was found to be more effective than allergy shots alone in providing long-lasting symptom relief.

SourceNIH/National Institute of Allergy and Infectious Diseases·JournalJournal of Allergy and Clinical Immunology·DateOct 11, 2022
SAMSUNG T9 Portable SSD 2TB

SAMSUNG T9 Portable SSD 2TB transfers large imagery and model outputs quickly between field laptops, lab workstations, and secure archives.

High risk/high reward federal grant funds effort to develop a smart drug delivery system to treat multiple Alzheimer’s pathologies all at once

Researchers have designed a smart cell-based delivery system to treat Alzheimer's disease by targeting multiple pathologies, reducing the risk of side effects. The system uses bio-synthesizable drugs and immune cells to deliver combination therapy that addresses all pathologies in a targeted manner.

SourceBuck Institute for Research on Aging·DateOct 4, 2022

Could monoclonal antibodies replace opioids for chronic pain?

Researchers at UC Davis aim to develop monoclonal antibodies that can bind to specific ion channels in nerve cells, inhibiting pain signal transmission. The goal is to create a monthly, non-addictive pain medication to replace opioids, which can lead to addiction.

SourceUniversity of California - Davis Health·DateSep 20, 2022

Infants, young children finally get relief from eczema’s terrible itch

A new biologic drug has been found to be highly effective in reducing the signs and symptoms of moderate-to-severe eczema in infants and young children. The study showed that more than half of treated children experienced a 75% reduction in eczema symptoms, leading to improved sleep and increased ability to lead normal lives.

SourceNorthwestern University·JournalThe Lancet·TypeRandomized controlled/clinical trial·DateSep 15, 2022
Sky-Watcher EQ6-R Pro Equatorial Mount

Sky-Watcher EQ6-R Pro Equatorial Mount provides precise tracking capacity for deep-sky imaging rigs during long astrophotography sessions.

Research reveals widespread use of ineffective COVID-19 treatments after FDA deauthorized their use

Physician-scientists at Beth Israel Deaconess Medical Center found that despite FDA deauthorization, a large number of doses of ineffective COVID-19 treatments were administered to patients in 2022, with wide variability by state. The study highlights the need for improved transparency and regulation of COVID-19 therapies.

SourceBeth Israel Deaconess Medical Center·JournalJAMA Network Open·DateAug 29, 2022

Using mRNA, Tufts researchers teach muscle cells to produce antibodies

Researchers at Tufts University have developed a novel mRNA-based approach to generate complex antibodies in muscle cells, which can be used to treat various diseases including botulism and cancer. The technique has shown promising results in neutralizing lethal doses of botulinum neurotoxins in mice.

SourceTufts University·JournalScientific Reports·TypeExperimental study·DateAug 25, 2022
GoPro HERO13 Black

GoPro HERO13 Black records stabilized 5.3K video for instrument deployments, field notes, and outreach, even in harsh weather and underwater conditions.

The AABB releases clinical practice guidelines for the appropriate use of COVID-19 convalescent plasma

The AABB has released clinical practice guidelines for the appropriate use of COVID-19 convalescent plasma, recommending its use for nonhospitalized patients at high risk for disease progression. The guidelines suggest that CCP is most effective when transfused with high neutralizing titers early after symptom onset.

SourceAmerican College of Physicians·JournalAnnals of Internal Medicine·TypeSystematic review·DateAug 15, 2022

Treating cancer by sticking cells in place

Researchers developed a monoclonal antibody that binds E-cadherin, strengthening cell adhesion and preventing cancer metastasis. The antibody, 19A11, has two binding modes that increase adhesive strength through salt bridge formation.

SourceUniversity of California - Davis·JournalProceedings of the National Academy of Sciences·TypeExperimental study·DateAug 4, 2022
Celestron NexStar 8SE Computerized Telescope

Celestron NexStar 8SE Computerized Telescope combines portable Schmidt-Cassegrain optics with GoTo pointing for outreach nights and field campaigns.

Demonstration of a potent, universal coronavirus monoclonal antibody therapy for all COVID-19 variants

Researchers discovered a potent universal coronavirus therapy that targets the S2 stalk region of the viral spike protein, highly conserved among beta-coronaviruses. The monoclonal antibody protected against infections when given as an intraperitoneal injection or nasal dose in animal experiments.

SourceUniversity of Alabama at Birmingham·JournalPLOS Pathogens·TypeExperimental study·DateJul 21, 2022

Messenger RNA technology shows promise for developing infectious disease therapeutics

Researchers at USAMRIID have demonstrated the use of messenger RNA (mRNA) to develop treatments for infectious diseases. The study found that administering mRNAs encoding monoclonal antibodies targeting poxviruses resulted in significant systemic levels of functional antibodies, offering potential for rapid response to disease outbreaks.

SourceUS Army Medical Research Institute of Infectious Diseases·JournalMolecular Therapy — Nucleic Acids·TypeExperimental study·DateJul 6, 2022

Patients treated with monoclonal antibodies during COVID-19 delta surge had low rates of severe disease, Mayo Clinic study finds

A Mayo Clinic study of 10,775 high-risk adult patients during the COVID-19 delta surge found that treatment with anti-spike neutralizing monoclonal antibodies led to low rates of severe disease, hospitalization, and mortality. The rates were lowest for patients treated with sotrovimab, with only 1.2% developing severe disease.

SourceMayo Clinic·JournalMayo Clinic Proceedings·DateJun 27, 2022
Apple iPad Pro 11-inch (M4)

Apple iPad Pro 11-inch (M4) runs demanding GIS, imaging, and annotation workflows on the go for surveys, briefings, and lab notebooks.

Beyond the spike: New antibody analysis predicts severe COVID-19 outcomes

Researchers analyzed antibodies to internal and surface proteins of SARS-CoV-2, finding that profiles of internal proteins predicted survival outcomes as well as those for surface proteins. The study suggests targeting other parts of the virus could enhance COVID-19 vaccines and therapies.

SourceUniversity of Pittsburgh·JournalCell Reports·TypeObservational study·DateJun 24, 2022

COVID-19: Identification of broadly SARS-CoV-2 neutralizing monoclonal antibodies

Scientists at Institut Pasteur developed potent neutralizing antibodies from convalescent COVID-19 individuals effective against various SARS-CoV-2 variants. These human antibodies are promising candidates for immunotherapies to prevent severe forms and/or treat COVID-19 in immunocompromised patients.

SourceInstitut Pasteur·JournalJournal of Experimental Medicine·TypeExperimental study·DateJun 17, 2022

Broadly neutralizing antibodies could provide immunity against SARS-CoV-2 variants

Researchers have identified two broadly neutralizing antibodies that can effectively neutralize all SARS-CoV-2 variants, including Omicron BA.1 and BA.2 subtypes. The antibodies, Cv2.1169 and Cv2.3194, were found to be fully active against Alpha, Beta, Gamma, and Delta variants.

SourceRockefeller University Press·JournalJournal of Experimental Medicine·TypeExperimental study·DateJun 15, 2022
Anker Laptop Power Bank 25,000mAh (Triple 100W USB-C)

Anker Laptop Power Bank 25,000mAh (Triple 100W USB-C) keeps Macs, tablets, and meters powered during extended observing runs and remote surveys.

Molecule that combines three distinct technologies against most aggressive type of brain cancer is tested

Researchers have developed a molecule that uses nanotechnology, chemotherapy and a monoclonal antibody to target glioblastoma multiforme, the most aggressive type of brain cancer. The treatment showed promise in isolated cells and animal models, with significant reductions in tumor volume and no increased toxicity.

SourceFundação de Amparo à Pesquisa do Estado de São Paulo·JournalInternational Journal of Pharmaceutics·DateJun 14, 2022

Good news on blocking a virus considered a global threat

Researchers developed an antibody cocktail effective against a Hendra virus variant, neutralizing its ability to mutate and evade recognition. The combination of four antibodies leaves the virus with minimal ability to further evolve, providing significant protection against this global biosecurity threat.

SourceOhio State University·JournalProceedings of the National Academy of Sciences·DateJun 13, 2022

Targeting molecular pathway that causes pulmonary arterial hypertension

Researchers at UC San Diego describe the underlying signaling pathway that causes PAH and a novel monoclonal antibody therapy that blocks abnormal blood vessel formation. The study reveals two opposing roles of NOTCH ligands and opens a door to a potentially new treatment for PAH.

SourceUniversity of California - San Diego·JournalScience Translational Medicine·DateMay 6, 2022
Kestrel 3000 Pocket Weather Meter

Kestrel 3000 Pocket Weather Meter measures wind, temperature, and humidity in real time for site assessments, aviation checks, and safety briefings.

Some cases of long COVID-19 may be caused by an abnormally suppressed immune system, UCLA-led research suggests

A UCLA-led team found that an abnormally suppressed immune system, not a persistently hyperactive one, may be to blame for some cases of long COVID-19. The study suggests boosting immunity in those individuals could be a treatment option.

SourceUniversity of California - Los Angeles Health Sciences·JournalClinical Infectious Diseases·TypeRandomized controlled/clinical trial·DateApr 22, 2022

COVID-19 therapy: Better in combination than alone

Researchers at Charité, MDC, and FU Berlin have studied the mechanisms of action of antibody and dexamethasone treatments for COVID-19. They found that combination therapy is more effective in reducing viral activity and inflammation in lung tissue, suggesting a potential game-changer in treating severe cases.

SourceCharité - Universitätsmedizin Berlin·JournalMolecular Therapy·TypeExperimental study·DateApr 13, 2022
AmScope B120C-5M Compound Microscope

AmScope B120C-5M Compound Microscope supports teaching labs and QA checks with LED illumination, mechanical stage, and included 5MP camera.

New tests and treatments developed in mice for pulmonary fibrosis

Scientists at University of Illinois and Mie University develop monoclonal antibodies to prevent lung cell death in mouse models of idiopathic pulmonary fibrosis and acute respiratory disease syndrome. Non-invasive diagnostic tools also presented could aid in predicting disease progression and identifying patients at risk.

SourceUniversity of Illinois College of Agricultural, Consumer and Environmental Sciences·JournalNature Communications·DateMar 23, 2022
Apple AirPods Pro (2nd Generation, USB-C)

Apple AirPods Pro (2nd Generation, USB-C) provide clear calls and strong noise reduction for interviews, conferences, and noisy field environments.

World-first CJD treatment shows promising early results

Researchers have developed a monoclonal antibody called PRN100, which showed safe and encouraging results in treating Creutzfeldt-Jakob disease (CJD) in six patients. While the findings are preliminary and require further studies, they offer new prospects for this rare and fatal disease.

SourceUniversity College London·JournalThe Lancet Neurology·TypeExperimental study·DateMar 16, 2022

How Omicron escapes from antibodies

A computational study finds that Omicron's spike protein has evolved to evade multiple classes of antibodies targeting SARS-CoV-2, even those from vaccinated individuals and monoclonal antibody treatments. The study suggests vaccines still offer protection due to the development of T cell immunity.

SourceMassachusetts Institute of Technology·TypeComputational simulation/modeling·DateFeb 1, 2022
DJI Air 3 (RC-N2)

DJI Air 3 (RC-N2) captures 4K mapping passes and environmental surveys with dual cameras, long flight time, and omnidirectional obstacle sensing.

New study adds more evidence for Omicron immune evasion

A new study finds that the Omicron variant can evade immunity from previous infections and vaccines, with antibodies from double-vaccinated individuals showing reduced neutralizing activity. The study suggests the need for new vaccines and treatments to combat evolving variants.

SourceColumbia University Irving Medical Center·JournalNature·TypeExperimental study·DateDec 23, 2021

mRNA vaccines highly effective at preventing death from COVID-19, less effective at preventing infection

Researchers found that mRNA vaccines were highly effective (86%) in preventing SARS-CoV-2-related deaths among vaccinated individuals, especially in the elderly population. However, vaccine effectiveness against infection was lower (69%) and decreased with increasing age and comorbidity burden.

SourceAmerican College of Physicians·JournalAnnals of Internal Medicine·TypeRandomized controlled/clinical trial·DateDec 20, 2021
Creality K1 Max 3D Printer

Creality K1 Max 3D Printer rapidly prototypes brackets, adapters, and fixtures for instruments and classroom demonstrations at large build volume.

Rapid test identifies antibody effectiveness against COVID-19 variants

A new rapid test developed by Duke University researchers can measure patient immunity against multiple COVID-19 variants like Omicron and Delta. The CoVariant-SCAN test uses a polymer brush coating to detect neutralizing antibodies, allowing for quick and accurate assessment of antibody effectiveness.

SourceDuke University·JournalScience Advances·TypeExperimental study·DateDec 3, 2021

Scientists create a new best-in-class anti-malarial antibody

Researchers at the Ragon Institute of MGH, MIT and Harvard have developed a new anti-malarial antibody that provides significant protection against malaria, outperforming existing best-in-class antibodies. The breakthrough could lead to improved distribution of monoclonal antibodies in endemic countries.

SourceMassachusetts General Hospital·JournalImmunity·TypeExperimental study·DateNov 16, 2021

Antibody treatment prevents inflammation in lungs, nervous system in macaques with SARS-CoV-2

A new study found that monoclonal antibodies protected aged, diabetic rhesus macaque monkeys from SARS-CoV-2 disease by reducing signs of inflammation. The treatment prevented viral RNA in the cerebrospinal fluid and infiltration of activated immune cells, suggesting a potential preventative measure for elderly residents during outbreaks.

SourceUniversity of California - Davis·JournalCell Reports·TypeExperimental study·DateNov 1, 2021
Rigol DP832 Triple-Output Bench Power Supply

Rigol DP832 Triple-Output Bench Power Supply powers sensors, microcontrollers, and test circuits with programmable rails and stable outputs.